ICON Public (NASDAQ:ICLR – Get Free Report) had its price target lifted by Truist Financial from $357.00 to $367.00 in a note issued to investors on Friday, Benzinga reports. The firm presently has a “buy” rating on the medical research company’s stock. Truist Financial’s target price would suggest a potential upside of 16.81% from the company’s current price.
A number of other brokerages have also recently issued reports on ICLR. JPMorgan Chase & Co. upped their price objective on shares of ICON Public from $295.00 to $330.00 and gave the stock an “overweight” rating in a report on Wednesday, December 20th. Barclays boosted their target price on shares of ICON Public from $280.00 to $325.00 and gave the stock an “overweight” rating in a research report on Thursday, January 25th. Finally, Citigroup boosted their target price on shares of ICON Public from $300.00 to $315.00 and gave the stock a “buy” rating in a research report on Monday, December 11th. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $312.64.
Get Our Latest Analysis on ICLR
ICON Public Price Performance
NASDAQ ICLR opened at $314.19 on Friday. The stock has a market capitalization of $25.87 billion, a P/E ratio of 42.57, a P/E/G ratio of 1.53 and a beta of 1.10. ICON Public has a 1 year low of $181.92 and a 1 year high of $323.80. The business’s fifty day moving average is $273.54 and its two-hundred day moving average is $261.77. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.19 and a current ratio of 1.21.
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in the stock. Chartwell Investment Partners LLC increased its stake in ICON Public by 23.5% in the fourth quarter. Chartwell Investment Partners LLC now owns 8,589 shares of the medical research company’s stock valued at $2,431,000 after acquiring an additional 1,636 shares during the period. LM Advisors LLC bought a new stake in ICON Public in the fourth quarter valued at about $26,000. State of Tennessee Treasury Department increased its stake in ICON Public by 4.9% in the fourth quarter. State of Tennessee Treasury Department now owns 155,797 shares of the medical research company’s stock valued at $44,101,000 after acquiring an additional 7,270 shares during the period. Crossmark Global Holdings Inc. bought a new stake in ICON Public in the fourth quarter valued at about $201,000. Finally, CIBC Private Wealth Group LLC increased its stake in ICON Public by 0.9% in the fourth quarter. CIBC Private Wealth Group LLC now owns 695,932 shares of the medical research company’s stock valued at $196,998,000 after acquiring an additional 6,331 shares during the period. Institutional investors and hedge funds own 95.21% of the company’s stock.
About ICON Public
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Recommended Stories
Receive News & Ratings for ICON Public Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for ICON Public and related companies with MarketBeat.com’s FREE daily email newsletter.
Source: americanbankingnews.com
